Patents by Inventor Hoi Ying LIN

Hoi Ying LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCEMENT OF CD47 BLOCKADE THERAPY WITH DHFR INHIBITORS
    Publication number: 20240423983
    Abstract: Materials and methods useful for therapy, including cancer therapy, that combine an agent that blocks the CD47/SIRP? interaction with a DHFR inhibitor are provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: December 26, 2024
    Applicant: PF Argentum IP Holdings LLC
    Inventors: Robert Adam UGER, Gloria Hoi Ying LIN
  • CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY
    Publication number: 20240018258
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
  • IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY EGFR ANTIBODY
    Publication number: 20210040219
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and an EGFR antibody such as cetuximab. The anti-cancer effect of cetuximab is enhanced in the presence of SIRP?Fc. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 11, 2021
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Robert Adam UGER
  • CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY
    Publication number: 20210040224
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 11, 2021
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
  • CD47 BLOCKADE THERAPY
    Publication number: 20200157179
    Abstract: CD47+ disease cells, such as various cancers, are treated using a combination of CD47 blockade with T cell checkpoint inhibition. Preferred embodiments use SIRP?Fc in combination with a PD-1 pathway inhibitor such as nivolumab and/or a CTLA-4 inhibitor such as ipilimumab.
    Type: Application
    Filed: March 27, 2018
    Publication date: May 21, 2020
    Applicant: Trillium Therapeutics Inc.
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Lisa Danae Schultz JOHNSON, Mark Michael WONG, Robert Adam UGER
  • HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS
    Publication number: 20200031825
    Abstract: Compounds of Formula I and II have been prepared for use in the treatment of diseases, disorders or conditions treatable by activation of the stimulator of interferon genes (STING) adaptor protein, such as in the treatment or prevention of cancers.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 30, 2020
    Applicant: Trillium Therapeutics Inc.
    Inventors: Abdelmalik Slassi, Peter DOVE, Zezhou WANG, Hoi Ying LIN, David Alexander ROSA, Jeffrey Todd WINSTON
  • MACROPHAGE STIMULATION IN CD47 BLOCKADE THERAPY
    Publication number: 20190091290
    Abstract: Blockade of the CD47/SIRPa pathway depletes cancer cells. This anti-cancer activity is enhanced when macrophage stimulating agents are used in combination with the CD47 blockade drug. This anti-cancer combination therapy is particularly effective when the CD47 blockade drug is SIRPaFc.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 28, 2019
    Inventors: Gloria Hoi Ying Lin, Natasja Nielsen Viller, Lisa Danae Schultz Johnson, Mark Michael Wong, Robert Adam Uger